Plain-English translation of NCT06794073 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a combination approach to treat advanced liver cancer that cannot be surgically removed. The study combines four types of treatment: an immunotherapy drug called Tislelizumab, a targeted cancer medication called lenvatinib, heat-based tumor destruction, and a catheter procedure that delivers chemotherapy directly to the liver. Researchers want to see if using these treatments together is safe and effective.
Advanced liver cancer that cannot be surgically removed is very difficult to treat, and current options have limited success. This trial is exploring whether combining multiple treatment approaches might work better than using them separately, potentially giving patients with this serious condition a more powerful treatment option.
You likely qualify if…
You likely don't qualify if…
You would start by taking the two immunotherapy medications for up to 2 weeks. Then you would receive the heat-based tumor destruction procedure at the hospital. After that, you may receive a catheter procedure to deliver chemotherapy directly to your liver if needed. Starting about a week after the heat therapy, you would resume taking the two medications and continue them until your cancer stops responding, you experience serious side effects, or you choose to stop. Throughout the trial, your doctors will monitor your response through imaging and blood tests.
AI-generated summary from trial data · Jul 20, 2026 · Not medical advice
China